Keyphrases
Pembrolizumab
100%
Colorectal Cancer
76%
Metastatic Colorectal Cancer (mCRC)
76%
Chemotherapy
59%
Advanced Solid Tumors
50%
Overall Survival
40%
Pancreatic Cancer
33%
Programmed Death-ligand 1 (PD-L1)
32%
Previously Treated
31%
Israeli
29%
Monotherapy
28%
Objective Response Rate
26%
Gastric Cancer
24%
Antitumor Activity
24%
Phase II Trial
23%
Neoadjuvant
22%
Colorectal Liver Metastases
22%
Treatment-related Adverse Events
21%
Oxaliplatin
20%
Clinical Outcomes
19%
Resection
18%
Liver
18%
First-in-class
18%
Colorectal Cancer Patients
18%
Pancreatic Neuroendocrine Tumors (pNETs)
17%
Colon Cancer
17%
Tumor
17%
Adjuvant Chemotherapy
17%
Progression-free Survival
17%
Primary Tumor
17%
Nonfunctional Pancreatic Neuroendocrine Tumor
16%
Confidence Interval
16%
Immune Checkpoint Inhibitors
16%
Immunoglobulin-like Transcript 4
16%
PD-1 Resistance
16%
Ramucirumab
16%
Selective Internal Radiation Therapy
16%
Specific Antibodies
16%
Resistance Mechanisms
16%
BRCA mutation
16%
Paclitaxel
16%
FOLFIRINOX
16%
Retrospective Analysis
15%
Pancreatic Ductal Adenocarcinoma
15%
Bevacizumab
15%
Germline mutation
14%
Ashkenazi
14%
Neoadjuvant Chemotherapy
14%
Jewish
13%
Cetuximab
13%
Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
88%
Solid Malignant Neoplasm
65%
Metastatic Colorectal Cancer
60%
Chemotherapy
59%
Malignant Neoplasm
54%
Neoplasm
47%
Disease
44%
Overall Survival
41%
Adverse Event
40%
Colorectal Cancer
36%
Pancreas Cancer
36%
Stomach Cancer
30%
Progression Free Survival
30%
Monotherapy
28%
Monoclonal Antibody
21%
Colon Cancer
21%
Antitumor Activity
20%
Adenocarcinoma
20%
Recurrent Disease
19%
Fluorouracil
19%
Pharmacokinetics
18%
Antibodies
16%
Ramucirumab
16%
Paclitaxel
16%
Combination Therapy
15%
Folinic Acid
15%
Oxaliplatin
15%
Cetuximab
14%
Digestive System Cancer
14%
Pancreas Adenocarcinoma
13%
Placebo
13%
Rectum Cancer
11%
Liver Metastasis
11%
Head and Neck Squamous Cell Carcinoma
10%
Pectin
10%
2,5-Dimethoxy-4-iodoamphetamine
10%
Chemoradiation Therapy
10%
Immunoglobulin Antibody
10%
Salicylate Sodium
10%
Prostate Cancer
10%
Chemokine Receptor
10%
Navarixin
10%
Bispecific Antibody
10%
Programmed Cell Death
10%
Immunotherapy
9%
Disease Exacerbation
9%
Chemotherapy Regimens
9%
Tolerability
9%
Programmed Death 1 Ligand 1
9%
Immune Checkpoint Inhibitor
8%
Medicine and Dentistry
Pembrolizumab
57%
Malignant Neoplasm
54%
Overall Survival
53%
Colorectal Cancer
53%
Pancreas Cancer
42%
Neoplasm
42%
Metastatic Colorectal Cancer
39%
Rectum Cancer
38%
Progression Free Survival
28%
Disease
27%
Metastatic Carcinoma
26%
Recurrent Disease
26%
Pancreas Islet Cell Tumor
25%
Surgery
23%
Stomach Cancer
22%
Adverse Event
22%
Chemoradiotherapy
20%
Gastroesophageal Junction
20%
Colon Cancer
18%
Placebo
17%
Primary Tumor
17%
Adjuvant Chemotherapy
17%
4 Iodo 2,5 Dimethoxyamphetamine
16%
BRCA Mutation
16%
Radiation Therapy
16%
Immune Checkpoint Inhibitor
14%
Neoadjuvant Chemotherapy
14%
Liver Metastasis
14%
Intention-to-Treat Analysis
13%
Colonoscopy
13%
Biological Marker
13%
Hepatectomy
12%
Oxaliplatin
12%
Clinical Trial
12%
Adenocarcinoma
12%
Antineoplastic Activity
12%
Monotherapy
12%
FOLFOX
12%
Neoadjuvant Therapy
11%
Family History
11%
Immunotherapy
11%
Breast Cancer
11%
Hepatocellular Carcinoma
11%
Colorectal Liver Metastasis
11%
Solid Malignant Neoplasm
10%
Antibodies
10%
Intraperitoneal Chemotherapy
10%
Ileostomy
10%
Selective Internal Radiation Therapy
10%
Peritoneum Metastasis
10%
